Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 165Sarcoma 37Gastrointestinal 12Thoracic 9Dermatologic 9Lymphoid 7Endocrine 7Genitourinary 5Tumor-Agnostic 4NET 3Breast 3Gynecologic 2Other solid neoplasm 1Other hematologic neoplasm 1

Conditions

Prostatic Neoplasms 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Melanoma 1Glioma 1Glioblastoma 1Fallopian Tube Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

Paclitaxel 161Fulvestrant 155Trastuzumab 152pembrolizumab 144Letrozole 136Carboplatin 118pertuzumab 104Cyclophosphamide 102Capecitabine 102Specimen Handling 101Anastrozole 90palbociclib 85abemaciclib 81Magnetic Resonance Spectroscopy 81exemestane 76Docetaxel 76Tamoxifen 75ribociclib 73trastuzumab deruxtecan 69Radiotherapy 61Biopsy 59Surveys and Questionnaires 56Gemcitabine 52130-nm albumin-bound paclitaxel 52sacituzumab govitecan 50olaparib 50Standard of Care 49Blood Specimen Collection 49Taxes 47Doxorubicin 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Temozolomide × Breast × 1 year × Clear all
NCT05417594 2026-06-02

CERTIS1

AstraZeneca

Phase 1/2 Recruiting
695 enrolled
BreastCNSGastrointestinalGenitourinaryGynecologic

Astrocytoma, Breast Neoplasms, Fallopian Tube Neoplasms, Glioma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT04478279 2026-02-09

A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors

Sapience Therapeutics

Phase 1/2 Active not recruiting
125 enrolled
BreastCNSDermatologicGenitourinary

Brain Neoplasms, Breast Neoplasms, Glioblastoma, Melanoma, Prostatic Neoplasms

NCT05128734 2025-12-15

Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)

AHS Cancer Control Alberta

Phase 2 Not yet recruiting
40 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡